Medicare Enrolled

Dr. Lakshmi Myneni, MD

Rheumatology · Mountain View, CA
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
2490 HOSPITAL DR STE 102, Mountain View, CA 94040
6509697006
In practice since 2006 (19 years)
NPI: 1316028533 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Myneni from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Myneni? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Myneni

Dr. Lakshmi Myneni is a rheumatology specialist in Mountain View, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Myneni performed 24,211 Medicare services across 457 unique beneficiaries.

Between the years covered by Open Payments, Dr. Myneni received a total of $7,764 from 28 pharmaceutical and/or device companies across 160 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Myneni is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 16% volume in CA $7,764 industry payments

Medicare Practice Summary

Medicare Utilization ↗
24,211
Medicare services
Top 16% in CA for rheumatology
457
Unique beneficiaries
$13
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,274 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Romosozumab injection (Evenity) for osteoporosis 14,910 $8 $20
Denosumab injection (Prolia/Xgeva) 8,580 $18 $45
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
287 $14 $125
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
160 $113 $340
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
156 $79 $245
Intravenous infusion, 1 hour or less
Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less.
34 $69 $450
Office visit, established patient (10-19 min)
An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition.
31 $45 $165
Telephone medical discussion, 11-20 minutes
A phone conversation with a physician lasting between 11 and 20 minutes.
22 $71 $250
Injection, methylprednisolone acetate, 40 mg 18 $6 $24
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
13 $170 $445
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.1% high complexity
98.3% medium
1.6% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$7,764
Total received (2018-2024)
Avg $1,109/year across 7 years
Top 33% in CA for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
28
Companies
160
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,013 (77.4%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,751 (22.6%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$2,170
2023
$1,924
2022
$634
2021
$464
2020
$465
2019
$1,288
2018
$818

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$1,751
Amgen Inc.
$193
AstraZeneca Pharmaceuticals LP
$63
PFIZER INC.
$53
GlaxoSmithKline, LLC.
$32
ABBVIE INC.
$27
Radius Health, Inc.
$26
Lilly USA, LLC
$26
Top 3 companies account for 92.5% of 2024 payments
All-time payments by company (2018-2024) ›
Janssen Biotech, Inc.
$1,926
US Oncology Corporate, Inc.
$1,139
Radius Health, Inc.
$818
Amgen Inc.
$740
AstraZeneca Pharmaceuticals LP
$375
UCB, Inc.
$318
PFIZER INC.
$307
GENZYME CORPORATION
$232
Sun Pharmaceutical Industries Inc.
$215
AbbVie, Inc.
$205
Lilly USA, LLC
$185
GlaxoSmithKline, LLC.
$173
NOVARTIS PHARMACEUTICALS CORPORATION
$153
Novartis Pharmaceuticals Corporation
$143
Allergan, Inc.
$125
Genentech USA, Inc.
$104
Mallinckrodt Hospital Products Inc.
$98
Mallinckrodt Enterprises LLC
$96
Horizon Therapeutics plc
$78
Mallinckrodt LLC
$69
AbbVie Inc.
$68
Alexion Pharmaceuticals, Inc.
$47
ABBVIE INC.
$45
Aurinia Pharma U.S., Inc.
$30
Merck Sharp & Dohme Corporation
$29
Grifols USA, LLC
$17
Celgene Corporation
$16
Myriad Genetic Laboratories, Inc.
$15
Top 3 companies account for 50.0% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AVSOLA · BENLYSTA · COSENTYX · Cequa · Cimzia · EVENITY · Enbrel · FABRAZYME · FASENRA · FORTEO · Gamunex-C · HUMIRA · Humira · ILUMYA · INFLECTRA · KEVZARA · KRYSTEXXA · LUPKYNIS · OCREVUS · Prolia · RENFLEXIS · RINVOQ · Repatha · Rituxan · SAPHNELO · SIMPONI · SIMPONI ARIA · SOLIRIS · Strensiq · TALTZ · TAVNEOS · TREMFYA · Tymlos · XELJANZ · ZINPLAVA · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (77%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a rheumatology specialist in Mountain View?
Compare rheumatologists in the Mountain View area by procedure volume, costs, and industry payment transparency.
Browse rheumatologists nearby

Geographic Context

Rheumatologists within 10 mi
71
Per 100K population
3.7
County median income
$159,674
Nearest hospital
EL CAMINO HEALTH
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Myneni is a mixed practice specialist, with above-average Medicare volume (top 16% in CA), with low-engagement industry engagement, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Myneni experienced with romosozumab injection (evenity) for osteoporosis?
Based on Medicare claims data, Dr. Myneni performed 14,910 romosozumab injection (evenity) for osteoporosis services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Myneni receive payments from pharmaceutical companies?
Yes. Dr. Myneni received a total of $7,764 from 28 companies across 160 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Myneni's costs compare to other rheumatologists in Mountain View?
Dr. Myneni's average Medicare payment per service is $13. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Myneni) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →